Sinovac Biotech Ltd (SVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2025 | 06-2024 | 06-2023 | 06-2022 | 06-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,157,512 | 1,075,129 | 1,646,760 | 6,867,094 | 6,856,360 |
| Marketable Securities | 5,777,750 | 9,502,185 | 9,425,778 | 4,988,240 | 2,973,701 |
| Receivables | 321,792 | 404,718 | 500,440 | 969,561 | 1,393,084 |
| Inventories | 109,137 | 153,524 | 182,735 | 266,864 | 407,663 |
| Other current assets | -2 | 0 | 5 | 3 | 1 |
| TOTAL | $10,376,790 | $11,148,280 | $11,769,030 | $13,115,090 | $11,689,010 |
| Non-Current Assets | |||||
| PPE Net | 858,557 | 934,614 | 1,058,962 | 949,422 | 636,846 |
| Investments And Advances | 498,786 | 681,345 | 657,767 | 697,115 | 0 |
| Intangibles | 86,593 | 7,844 | 8,753 | 1,315 | 1,400 |
| Other Non-Current Assets | 166,339 | 124,854 | 230,503 | 302,845 | 300,556 |
| TOTAL | $1,610,275 | $1,748,657 | $1,955,985 | $1,950,697 | $938,802 |
| Total Assets | $11,987,070 | $12,896,940 | $13,725,010 | $15,065,780 | $12,627,810 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 214,962 | 179,349 | 201,118 | 104 | 22,358 |
| Accounts payable and accrued liabilities | 590,132 | 641,579 | 819,530 | 334,294 | 958,867 |
| Other current liabilities | 1,743 | 805 | 4,132 | 11,209 | 14,594 |
| TOTAL | $5,001,408 | $978,451 | $1,189,629 | $564,861 | $3,307,744 |
| Non-Current Liabilities | |||||
| Long Term Debt | 233,056 | 130,320 | 10,989 | 16,629 | 18,747 |
| Deferred Revenues | 12,007 | 6,173 | 139,547 | 32,763 | 334,664 |
| Other Non-Current Liabilities | 17,086 | 18,801 | 48,107 | 64,520 | 115,029 |
| TOTAL | $642,179 | $411,490 | $298,125 | $407,066 | $189,905 |
| Total Liabilities | $5,643,587 | $1,389,941 | $1,487,754 | $971,927 | $3,497,649 |
| Shareholders' Equity | |||||
| Common Shares | 72 | 100 | 100 | 100 | 99 |
| Retained earnings | 2,858,502 | 7,107,644 | 7,239,947 | 7,623,373 | 5,249,609 |
| Other shareholders' equity | 2,934,738 | 3,857,983 | 4,455,940 | 5,922,681 | 3,339,966 |
| TOTAL | $6,343,480 | $11,507,000 | $12,237,260 | $14,093,860 | $9,130,162 |
| Total Liabilities And Equity | $11,987,067 | $12,896,941 | $13,725,014 | $15,065,787 | $12,627,811 |